XML 41 R30.htm IDEA: XBRL DOCUMENT v3.10.0.1
Stockholders' equity (Tables)
12 Months Ended
Dec. 31, 2018
Equity [Abstract]  
Restricted stock activity
The Company’s restricted stock activity under the 2006 Plan and the 2016 Plan is summarized as follows:
 
 
Shares
 
Weighted
average grant
date fair value
Unvested at December 31, 2017
 
2,697

 
$
11.37

Granted
 
11,151

 
2.50

Vested
 
(4,981
)
 
5.50

Unvested at December 31, 2018
 
8,867

 
$
3.51

Stock option activity
The Company’s option activity under the 2006 Plan and the 2016 Plan is summarized as follows:
 
 
Number of
options
 
Weighted
average
exercise price
Outstanding at December 31, 2017
 
227,203

 
$
9.39

Issued
 
113,561

 
2.50

Expired
 
(800
)
 
9.90

Outstanding at December 31, 2018
 
339,964

 
$
7.09

Exercisable at December 31, 2018
 
303,986

 
$
6.94

Options outstanding and exercisable
The following table summarizes information about options outstanding and exercisable at December 31, 2018:
Weighted
average exercise
price of outstanding
options
 
Number of
options
outstanding
 
Weighted
average remaining
estimated life
(in years)
 
Number of
options
exercisable
 
Weighted average
price of outstanding
and exercisable
options
$2.50 - $5.70
 
204,034

 
5.6
 
185,985

 
 
$6.90 - $9.60
 
53,175

 
3.7
 
53,175

 
 
$10.50 - $10.80
 
4,000

 
5.1
 
4,000

 
 
$14.20 - $23.40
 
78,755

 
7.2
 
60,826

 
 
 
 
339,964

 
 
 
303,986

 
$6.94
Fair value of stock option grants to employees and board of directors
The fair values of stock option grants to employees and members of the Board of Directors during 2018, 2017, and 2016 were measured on the date of grant using Black-Scholes, with the following weighted average assumptions:
 
 
2018
 
2017
 
2016
Expected volatility
 
81%
 
78%
 
53%
Risk free interest rate
 
2.60%
 
1.80%
 
1.31%
Expected dividend yield
 
0.0%
 
0.0%
 
0.0%
Expected life (in years)
 
5
 
5
 
5
Share-based compensation related costs
The following table summarizes share-based compensation costs recognized in the Company’s Consolidated Statements of Operations and Comprehensive Loss for the years ended December 31, 2018, 2017, and 2016:
 
 
2018
 
2017
 
2016
Research and development
 
$
3,238

 
$
3,168

 
$
2,115

Sales and marketing
 

 
9,315

 
65,517

General and administrative
 
260,158

 
109,651

 
150,662

Total share-based compensation
 
$
263,396

 
$
122,134

 
$
218,294